Sunday, November 8, 2026

USD/CNH Bearish Momentum: 0.93% Down In The Last 10 Sessions

ViaNews Editorial Team

September 24, 2023

USD/CNH Bearish Momentum: 0.93% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 0.93% for the last 10 sessions. At 16:06 EST on Sunday, 24 September, USD/CNH (USDCNH) is $7.29.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0.003% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be oversold (<=20).

News about

  • Eur/usd remains under selling pressure near 1.0650, investors await eurozone, US PMI. According to FXStreet on Friday, 22 September, "This, in turn, boosts the Greenback and acts as a headwind for the EUR/USD pair. ", "Traders will take cues from these figures and find trading opportunities around the EUR/USD pair."
  • Eur/usd treading water near 1.0660, hanging near the top of the range. According to FXStreet on Friday, 22 September, "Hourly candles see the EUR/USD trading just south of the 200-hour Simple Moving Average (SMA) near 1.0685.", "The EUR/USD is trading into neutral ground heading into the end of the trading week, testing well-trodded ground near the 1.0660 handle."
  • Eur/usd forecast: faces challenging times amidst consolidation and US dollar strength - 22 September 2023. According to DailyForex on Friday, 22 September, "In this environment, the Euro is expected to continue facing difficulties, although short-term rallies may provide opportunities to acquire "cheap US dollars." A decisive break below the session's low on Thursday could potentially pave the way for the EUR/USD pair to descend towards the 1.05 level. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com